Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis

ConclusionsEverolimus reduces the risk of disease progression in hormone receptor (+) MBC. In patients with HER2 (+) disease, the benefit is limited for those with hormone receptor ( −) disease. Given the approval and use of newer drugs in MBC, clinical trials and real-world data are needed to confirm the benefit of everolimus and define the best treatment sequence strategy to adopt in that setting.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research